Drug Profile
Rodatristat ethyl - Sumitomo Pharma America
Alternative Names: KAR-5585; RVT-014; RVT-1201Latest Information Update: 16 Nov 2023
Price :
$50
*
At a glance
- Originator Karos Pharmaceuticals
- Developer Altavant Sciences; Sumitomo Pharma America
- Class Antifibrotics; Antihypertensives; Aza compounds; Chlorobenzenes; Fluorinated hydrocarbons; Hepatoprotectants; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action Tryptophan hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension
- Phase I Idiopathic pulmonary fibrosis
- Research Non-alcoholic fatty liver disease
- No development reported Sarcoidosis
Most Recent Events
- 09 Sep 2023 Pharmacokinetics and adverse events data from a phase IIb ELEVATE 2 trial in Pulmonary arterial hypertension presented at 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 28 Jul 2023 Enzyvant (previously Altavant Sciences) completes a phase I clinical trial in healthy volunteers in USA (PO) (NCT05933447)
- 05 Jun 2023 Altavant Sciences completes the phase-II ELEVATE 2 trial in Pulmonary arterial hypertension in US, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Czech Republic, England, France, Germany, Italy, Latvia, Moldova, Poland, Russia, Serbia, Spain, Ukraine, United Kingdom (PO) (NCT04712669)